Your browser doesn't support javascript.
Impaired physical function in patients with idiopathic inflammatory myopathies: results from the multicentre COVAD patient-reported e-survey.
Yoshida, Akira; Kim, Minchul; Kuwana, Masataka; Naveen, R; Makol, Ashima; Sen, Parikshit; Lilleker, James B; Agarwal, Vishwesh; Kardes, Sinan; Day, Jessica; Milchert, Marcin; Joshi, Mrudula; Gheita, Tamer; Salim, Babur; Velikova, Tsvetelina; Edgar Gracia-Ramos, Abraham; Parodis, Ioannis; O'Callaghan, Albert Selva; Nikiphorou, Elena; Chatterjee, Tulika; Tan, Ai Lyn; Nune, Arvind; Cavagna, Lorenzo; Saavedra, Miguel A; Shinjo, Samuel Katsuyuki; Ziade, Nelly; Knitza, Johannes; Distler, Oliver; Chinoy, Hector; Agarwal, Vikas; Aggarwal, Rohit; Gupta, Latika.
  • Yoshida A; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
  • Kim M; Center for Outcomes Research, Department of Internal Medicine, University of Illinois College of Medicine Peoria, Illinois, USA.
  • Kuwana M; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
  • Naveen R; Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
  • Makol A; Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Sen P; Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India.
  • Lilleker JB; Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
  • Agarwal V; Neurology, Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, UK.
  • Kardes S; Mahatma Gandhi Mission Medical College, Navi Mumbai, Maharashtra, India.
  • Day J; Department of Medical Ecology and Hydroclimatology, Istanbul Faculty of Medicine, Istanbul University, Capa-Fatih, 34093, Istanbul, Turkey.
  • Milchert M; Department of Rheumatology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia.
  • Joshi M; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
  • Gheita T; Department of Medical Biology, University of Melbourne, Parkville, VIC, 3052, Australia.
  • Salim B; Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, ul Unii Lubelskiej 1, 71-252, Szczecin, Poland.
  • Velikova T; Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India.
  • Edgar Gracia-Ramos A; Rheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt.
  • Parodis I; Rheumatology Department, Fauji Foundation Hospital, Rawalpindi, Pakistan.
  • O'Callaghan AS; Department of Clinical Immunology, Medical Faculty, University Hospital "Lozenetz", Sofia University St. Kliment Ohridski, 1 Kozyak Str, Sofia, 1407, Bulgaria.
  • Nikiphorou E; Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, C.P. 02990, Mexico, Del. Azcapotzalco, Mexico City.
  • Chatterjee T; Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Tan AL; Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Nune A; Systemic Autoimmune Diseases Unit, Internal Medicine Department, Vall D'hebron General Hospital, Universitat Autonoma de Barcelona, Barcelona, 08035, Spain.
  • Cavagna L; Centre for Rheumatic Diseases, King's College London, London, UK.
  • Saavedra MA; Rheumatology Department, King's College Hospital, London, UK.
  • Shinjo SK; Center for Outcomes Research, Department of Internal Medicine, University of Illinois College of Medicine Peoria, Illinois, USA.
  • Ziade N; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK.
  • Knitza J; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
  • Distler O; Southport and Ormskirk Hospital NHS Trust, Southport, PR8 6PN, UK.
  • Chinoy H; Department of Rheumatology, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy.
  • Agarwal V; Rheumatology Unit, Dipartimento di Medicine Interna e Terapia Medica, Università degli studi di Pavia, Pavia, Lombardy, Italy.
  • Aggarwal R; Departamento de Reumatología Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, IMSS, Mexico City, Mexico.
  • Gupta L; Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.
Rheumatology (Oxford) ; 2022 Aug 03.
Article in English | MEDLINE | ID: covidwho-2287960
ABSTRACT

OBJECTIVES:

The assessment of physical function is fundamental in the management of patients with idiopathic inflammatory myopathies (IIMs). We aimed to investigate the physical function of patients with IIMs compared with those with non-IIM autoimmune rheumatic diseases (AIRDs) utilizing Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function (PF) data obtained in the COVAD study, an international self-reported e-survey assessing the safety of COVID-19 vaccines in AIRDs.

METHODS:

Demographics, AIRD diagnosis, disease activity, and PROMIS PF short form-10a data were extracted from the COVAD database. PROMIS PF-10a scores were compared between disease categories and stratified by disease activity. Factors affecting PROMIS PF-10a scores other than disease activity were identified by multivariable regression analysis in patients with inactive disease.

RESULTS:

1057 IIM patients, 3635 non-IIM AIRD patients, and 3981 healthy controls (HCs) responded to the COVAD e-survey from April to August 2021. Using a binomial regression model, the predicted mean of PROMIS PF-10a scores was significantly lower in IIM patients compared with non-IIM AIRD patients or HCs (36.3 [95% confidence interval (CI) 35.5-37.1] vs 41.3 [95%CI 40.2-42.5] vs 46.2 [95%CI 45.8-46.6], P < 0.001), irrespective of disease activity. The independent factors for lower PROMIS PF-10a scores in patients with inactive disease were older age, female, longer disease duration, and a diagnosis of inclusion body myositis or polymyositis.

CONCLUSION:

Physical function is significantly impaired in IIMs compared with non-IIM AIRDs or HCs, even in patients with inactive disease. Our study highlights a critical need for better strategies to minimize functional disability in patients with IIMs.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Topics: Vaccines Language: English Journal subject: Rheumatology Year: 2022 Document Type: Article Affiliation country: Rheumatology

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Topics: Vaccines Language: English Journal subject: Rheumatology Year: 2022 Document Type: Article Affiliation country: Rheumatology